Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden.

Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P.

Int J Technol Assess Health Care. 2009 Jul;25(3):350-8. doi: 10.1017/S0266462309990079.

PMID:
19619354
2.

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.

Curr Med Res Opin. 2008 May;24(5):1417-28. doi: 10.1185/030079908X297295 . Epub 2008 Apr 8.

PMID:
18400145
3.

Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective.

Lindgren P, Lindström J, Tuomilehto J, Uusitupa M, Peltonen M, Jönsson B, de Faire U, Hellénius ML; DPS Study Group.

Int J Technol Assess Health Care. 2007 Spring;23(2):177-83.

PMID:
17493303
4.

Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study.

Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA.

Diabetes Care. 2007 Jan;30(1):128-34.

PMID:
17192345
5.

Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.

Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G; KORA Study Group.

Diabet Med. 2007 May;24(5):473-80. Epub 2007 Mar 22.

PMID:
17381502
6.

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.

Greving JP, Buskens E, Koffijberg H, Algra A.

Circulation. 2008 Jun 3;117(22):2875-83. doi: 10.1161/CIRCULATIONAHA.107.735340. Epub 2008 May 27.

7.

Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden.

Lindholm L, Rosén M, Weinehall L, Asplund K.

J Epidemiol Community Health. 1996 Apr;50(2):190-5.

8.

Cost-effectiveness of diabetes self-management programs in community primary care settings.

Brownson CA, Hoerger TJ, Fisher EB, Kilpatrick KE.

Diabetes Educ. 2009 Sep-Oct;35(5):761-9. doi: 10.1177/0145721709340931. Epub 2009 Jul 21.

PMID:
19622716
9.
10.

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.

Lindgren P, Geborek P, Kobelt G.

Int J Technol Assess Health Care. 2009 Apr;25(2):181-9. doi: 10.1017/S0266462309090230. Epub 2009 Mar 31.

PMID:
19331709
11.

Cost effectiveness of community-based physical activity interventions.

Roux L, Pratt M, Tengs TO, Yore MM, Yanagawa TL, Van Den Bos J, Rutt C, Brownson RC, Powell KE, Heath G, Kohl HW 3rd, Teutsch S, Cawley J, Lee IM, West L, Buchner DM.

Am J Prev Med. 2008 Dec;35(6):578-88. doi: 10.1016/j.amepre.2008.06.040.

PMID:
19000846
12.

The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.

Gift TL, Gaydos CA, Kent CK, Marrazzo JM, Rietmeijer CA, Schillinger JA, Dunne EF.

Sex Transm Dis. 2008 Nov;35(11 Suppl):S66-75. doi: 10.1097/OLQ.0b013e31818b64ac.

PMID:
18830137
13.

Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial.

Zethraeus N, Borgström F, Jönsson B, Kanis J.

Int J Technol Assess Health Care. 2005 Fall;21(4):433-41.

PMID:
16262965
14.

Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men.

Kahn JG, Kegeles SM, Hays R, Beltzer N.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):482-91.

PMID:
11511826
15.

The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease.

Lowensteyn I, Coupal L, Zowall H, Grover SA.

J Cardiopulm Rehabil. 2000 May-Jun;20(3):147-55.

PMID:
10860196
16.

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.

PMID:
19640359
17.

Lifestyle intervention to prevent diabetes: intensive and cost effective.

Wylie-Rosett J, Herman WH, Goldberg RB.

Curr Opin Lipidol. 2006 Feb;17(1):37-44.

PMID:
16407714
18.

Primary prevention of cardiovascular disease: cost-effectiveness comparison.

Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L.

Int J Technol Assess Health Care. 2007 Winter;23(1):71-9.

PMID:
17234019
19.

The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action.

Bemelmans W, van Baal P, Wendel-Vos W, Schuit J, Feskens E, Ament A, Hoogenveen R.

Prev Med. 2008 Feb;46(2):127-32. Epub 2007 Aug 3.

PMID:
17822752
20.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932

Supplemental Content

Support Center